Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Metastasis | Research

Development and validation of nomogram of peritoneal metastasis in gastric cancer based on simplified clinicopathological features and serum tumor markers

Authors: Jia Yang, Hongtao Su, Tao Chen, Xinhua Chen, Hao Chen, Guoxin Li, Jiang Yu

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Peritoneal metastasis (PM) is not uncommon in patients with gastric cancer(GC), which affects clinical treatment decisions, but the relevant examination measures are not efficiently detected. Our goal was to develop a clinical radiomics nomogram to better predict peritoneal metastases.

Methods

A total of 3480 patients from 2 centers were divided into 1 training, 1 internal validation, and 1 external validation cohort(1949 in the internal training set, 704 in the validation set, and 827 in the external validation cohort) with clinicopathologically confirmed GC. We recruited 11 clinical factors, including age, sex, smoking status, tumor size, differentiation, Borrmann type, location, clinical T stage, and serum tumor markers (STMs) comprising carbohydrate antigen 19–9 (CA19-9), carbohydrate antigen 72–4 (CA72-4), and carcinoembryonic antigen (CEA), to develop the radiomics nomogram. For clinical predictive feature selection and the establishment of clinical models, statistical methods of analysis of variance (ANOVA), relief and recursive feature elimination (RFE) and logistic regression analysis were used. To develop combined predictive models, tumor diameter, type, and location, clinical T stage and STMs were finally selected. The discriminatory ability of the nomogram to predict PM was evaluated by the area under the receiver operating characteristic curve(AUC), and decision curve analysis (DCA) was conducted to evaluate the clinical usefulness of the nomogram.

Results

The AUC of the clinical models was 0.762 in the training cohorts, 0.772 in the internal validation cohort, and 0.758 in the external validation cohort. However, when combined with STMs, the AUC was improved to 0.806, 0.839 and 0.801, respectively. DCA showed that the combined nomogram was of good clinical evaluation value to predict PM in GC.

Conclusions

The present study proposed a clinical nomogram with a combination of clinical risk factors and radiomics features that can potentially be applied in the individualized preoperative prediction of PM in GC patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Thrift AP, El-Serag HB. Burden of Gastric Cancer. Clin Gastroenterol Hepatol. 2020;18(3):534–42.CrossRef Thrift AP, El-Serag HB. Burden of Gastric Cancer. Clin Gastroenterol Hepatol. 2020;18(3):534–42.CrossRef
2.
go back to reference Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRef Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRef
3.
go back to reference Fock KM. Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther. 2014;40(3):250–60.CrossRef Fock KM. Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther. 2014;40(3):250–60.CrossRef
4.
go back to reference Machlowska J, et al. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. 2020;21(11):4012.CrossRef Machlowska J, et al. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. 2020;21(11):4012.CrossRef
5.
go back to reference Soerjomataram I, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet. 2012;380(9856):1840–50.CrossRef Soerjomataram I, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet. 2012;380(9856):1840–50.CrossRef
6.
go back to reference Zheng TH, Zhao JL, Guleng B. Advances in molecular biomarkers for gastric cancer. Crit Rev Eukaryot Gene Expr. 2015;25(4):299–305.CrossRef Zheng TH, Zhao JL, Guleng B. Advances in molecular biomarkers for gastric cancer. Crit Rev Eukaryot Gene Expr. 2015;25(4):299–305.CrossRef
7.
go back to reference Matsuoka T, Yashiro M. Biomarkers of gastric cancer: Current topics and future perspective. World J Gastroenterol. 2018;24(26):2818–32.CrossRef Matsuoka T, Yashiro M. Biomarkers of gastric cancer: Current topics and future perspective. World J Gastroenterol. 2018;24(26):2818–32.CrossRef
8.
go back to reference Guo L, et al. Prognostic value of combination of inflammatory and tumor markers in Resectable gastric cancer. J Gastrointest Surg. 2021;25(10):2470–83.CrossRef Guo L, et al. Prognostic value of combination of inflammatory and tumor markers in Resectable gastric cancer. J Gastrointest Surg. 2021;25(10):2470–83.CrossRef
9.
go back to reference Qiu MZ, et al. Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China. J Transl Med. 2013;11:58.CrossRef Qiu MZ, et al. Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China. J Transl Med. 2013;11:58.CrossRef
10.
go back to reference Pinto-De-Sousa J, et al. Clinicopathologic profiles and prognosis of gastric carcinomas from the cardia, fundus/body and antrum. Dig Surg. 2001;18(2):102–10.CrossRef Pinto-De-Sousa J, et al. Clinicopathologic profiles and prognosis of gastric carcinomas from the cardia, fundus/body and antrum. Dig Surg. 2001;18(2):102–10.CrossRef
11.
go back to reference Riihimaki M, et al. Metastatic spread in patients with gastric cancer. Oncotarget. 2016;7(32):52307–16.CrossRef Riihimaki M, et al. Metastatic spread in patients with gastric cancer. Oncotarget. 2016;7(32):52307–16.CrossRef
12.
go back to reference Ye T, et al. MicroRNA-7 as a potential therapeutic target for aberrant NF-kappaB-driven distant metastasis of gastric cancer. J Exp Clin Cancer Res. 2019;38(1):55.CrossRef Ye T, et al. MicroRNA-7 as a potential therapeutic target for aberrant NF-kappaB-driven distant metastasis of gastric cancer. J Exp Clin Cancer Res. 2019;38(1):55.CrossRef
13.
go back to reference Zhao G, et al. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer. Medicine (Baltimore). 2020;99(10):e19405.CrossRef Zhao G, et al. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer. Medicine (Baltimore). 2020;99(10):e19405.CrossRef
14.
go back to reference Yoo CH, et al. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000;87(2):236–42.CrossRef Yoo CH, et al. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000;87(2):236–42.CrossRef
15.
go back to reference Sasako M, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359(5):453–62.CrossRef Sasako M, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359(5):453–62.CrossRef
16.
go back to reference Wang Z, Chen JQ. Imaging in assessing hepatic and peritoneal metastases of gastric cancer: a systematic review. BMC Gastroenterol. 2011;11:19.CrossRef Wang Z, Chen JQ. Imaging in assessing hepatic and peritoneal metastases of gastric cancer: a systematic review. BMC Gastroenterol. 2011;11:19.CrossRef
17.
go back to reference Royston P, et al. Prognosis and prognostic research: Developing a prognostic model. BMJ. 2009;338:b604.CrossRef Royston P, et al. Prognosis and prognostic research: Developing a prognostic model. BMJ. 2009;338:b604.CrossRef
18.
go back to reference Sawaki K, et al. Troponin I2 as a specific biomarker for prediction of peritoneal metastasis in gastric cancer. Ann Surg Oncol. 2018;25(7):2083–90.CrossRef Sawaki K, et al. Troponin I2 as a specific biomarker for prediction of peritoneal metastasis in gastric cancer. Ann Surg Oncol. 2018;25(7):2083–90.CrossRef
19.
go back to reference Wang R, et al. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. 2020;69(1):18–31.CrossRef Wang R, et al. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. 2020;69(1):18–31.CrossRef
20.
go back to reference Hu Y, et al. Malignant ascites-derived exosomes promote peritoneal tumor cell dissemination and reveal a distinct miRNA signature in advanced gastric cancer. Cancer Lett. 2019;457:142–50.CrossRef Hu Y, et al. Malignant ascites-derived exosomes promote peritoneal tumor cell dissemination and reveal a distinct miRNA signature in advanced gastric cancer. Cancer Lett. 2019;457:142–50.CrossRef
21.
go back to reference Kanda M, et al. Significance of SYT8 For the Detection, Prediction, and Treatment of Peritoneal Metastasis From Gastric Cancer. Ann Surg. 2018;267(3):495–503.CrossRef Kanda M, et al. Significance of SYT8 For the Detection, Prediction, and Treatment of Peritoneal Metastasis From Gastric Cancer. Ann Surg. 2018;267(3):495–503.CrossRef
22.
go back to reference Chen D, et al. Predicting postoperative peritoneal metastasis in gastric cancer with serosal invasion using a collagen nomogram. Nat Commun. 2021;12(1):179.CrossRef Chen D, et al. Predicting postoperative peritoneal metastasis in gastric cancer with serosal invasion using a collagen nomogram. Nat Commun. 2021;12(1):179.CrossRef
23.
go back to reference Jiang Y, et al. Noninvasive Prediction of Occult Peritoneal Metastasis in Gastric Cancer Using Deep Learning. JAMA Netw Open. 2021;4(1): e2032269.CrossRef Jiang Y, et al. Noninvasive Prediction of Occult Peritoneal Metastasis in Gastric Cancer Using Deep Learning. JAMA Netw Open. 2021;4(1): e2032269.CrossRef
24.
go back to reference Mirniaharikandehei S, et al. Applying a random projection algorithm to optimize machine learning model for predicting peritoneal metastasis in gastric cancer patients using CT images. Comput Methods Programs Biomed. 2021;200:105937.CrossRef Mirniaharikandehei S, et al. Applying a random projection algorithm to optimize machine learning model for predicting peritoneal metastasis in gastric cancer patients using CT images. Comput Methods Programs Biomed. 2021;200:105937.CrossRef
25.
go back to reference Zhou C, et al. Predicting Peritoneal Metastasis of Gastric Cancer Patients Based on Machine Learning. Cancer Control. 2020;27(1):1073274820968900.CrossRef Zhou C, et al. Predicting Peritoneal Metastasis of Gastric Cancer Patients Based on Machine Learning. Cancer Control. 2020;27(1):1073274820968900.CrossRef
26.
go back to reference Nakamura N, et al. The neutrophil/lymphocyte ratio as a predictor of peritoneal metastasis during staging laparoscopy for advanced gastric cancer: a retrospective cohort analysis. World J Surg Oncol. 2019;17(1):108.CrossRef Nakamura N, et al. The neutrophil/lymphocyte ratio as a predictor of peritoneal metastasis during staging laparoscopy for advanced gastric cancer: a retrospective cohort analysis. World J Surg Oncol. 2019;17(1):108.CrossRef
27.
go back to reference Qin R, et al. The Value of Serum Immunoglobulin G Glycome in the Preoperative Discrimination of Peritoneal Metastasis from Advanced Gastric Cancer. J Cancer. 2019;10(12):2811–21.CrossRef Qin R, et al. The Value of Serum Immunoglobulin G Glycome in the Preoperative Discrimination of Peritoneal Metastasis from Advanced Gastric Cancer. J Cancer. 2019;10(12):2811–21.CrossRef
28.
go back to reference Hasbahceci M, et al. Use of serum and peritoneal CEA and CA19-9 in prediction of peritoneal dissemination and survival of gastric adenocarcinoma patients: are they prognostic factors? Ann R Coll Surg Engl. 2018;100(4):257–66.CrossRef Hasbahceci M, et al. Use of serum and peritoneal CEA and CA19-9 in prediction of peritoneal dissemination and survival of gastric adenocarcinoma patients: are they prognostic factors? Ann R Coll Surg Engl. 2018;100(4):257–66.CrossRef
Metadata
Title
Development and validation of nomogram of peritoneal metastasis in gastric cancer based on simplified clinicopathological features and serum tumor markers
Authors
Jia Yang
Hongtao Su
Tao Chen
Xinhua Chen
Hao Chen
Guoxin Li
Jiang Yu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10537-7

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine